Studying Blood Toxicity in Workers Exposed to Formaldehyde
- Formaldehyde has many uses in industry and medicine. However, exposure to formaldehyde has been associated with increased risk for myeloid leukemia. There are still questions about how the chemical reacts with bone marrow to increase this cancer risk. Some smaller studies have looked at how it affects stem cells, which are found in bone marrow. Researchers want to develop a much larger study of workers in China. The study will look at different levels of formaldehyde exposure. It will focus on how the chemical affects the blood cells and bone marrow.
- To study the effects of formaldehyde exposure on blood cells and bone marrow.
- Individuals between 18 and 60 years of age who work in selected factories in Guangdong Province, China.
- Participants will be screened with a physical exam and medical history. They will also be screened with a work history. Those who have been exposed to benzene, butadiene, styrene, or radiation will not be included.
- Participants will be studied based on their regular formaldehyde exposure level. One-third will be those exposed to more than 1 part per million (ppm) of the chemical. One-third will be those exposed to 0.3 to 1 ppm. A control group will have no exposure to formaldehyde or any other known toxic chemical.
- Participants will provide blood and cheek swab samples. They will also answer questions about their work habits.
- To look at chemical exposure levels, participants will wear a small monitor to work on 3 different days. They may provide additional blood and cell samples as directed.
- No treatment will be provided as part of this study.
|Study Design:||Time Perspective: Cross-Sectional|
|Official Title:||A Cross-Sectional Study of Hematotoxicity in Workers Exposed to Formaldehyde|
- Hematotoxicity Change [ Time Frame: 2012-2024 ] [ Designated as safety issue: No ]
- Immune Function [ Time Frame: 2012- 2024 ] [ Designated as safety issue: No ]
|Study Start Date:||February 2012|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01547858
|United States, Maryland|
|National Cancer Institute (NCI), 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Qing Lan, M.D.||National Cancer Institute (NCI)|